97 related articles for article (PubMed ID: 26026911)
21. Overview of piperlongumine analogues and their therapeutic potential.
Zhu P; Qian J; Xu Z; Meng C; Zhu W; Ran F; Zhang W; Zhang Y; Ling Y
Eur J Med Chem; 2021 Aug; 220():113471. PubMed ID: 33930801
[TBL] [Abstract][Full Text] [Related]
22. Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3.
Jimenez L; Silva A; Calissi G; Grenho I; Monteiro R; Mayoral-Varo V; Blanco-Aparicio C; Pastor J; Bustos V; Bracher F; Megías D; Ferreira BI; Link W
J Gerontol A Biol Sci Med Sci; 2022 Aug; 77(8):1485-1493. PubMed ID: 34508571
[TBL] [Abstract][Full Text] [Related]
23. Piperlongumine as anticancer agent: The story so far about killing many birds with one stone.
Farooqi AA; Attar R; Yaylim I; Qureshi MZ; Todorovska M; Karatoprak GŞ; Najafi S; Sabitaliyevich UY; Zhenisovna TG; De Sousa DP; Lin X
Cell Mol Biol (Noisy-le-grand); 2018 Aug; 64(11):102-107. PubMed ID: 30213297
[TBL] [Abstract][Full Text] [Related]
24. Small Molecule Inhibitors of CRM1.
Ferreira BI; Cautain B; Grenho I; Link W
Front Pharmacol; 2020; 11():625. PubMed ID: 32574233
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs.
Adams DJ; Dai M; Pellegrino G; Wagner BK; Stern AM; Shamji AF; Schreiber SL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15115-20. PubMed ID: 22949699
[TBL] [Abstract][Full Text] [Related]
26. Activity-based protein profiling reveals GSTO1 as the covalent target of piperlongumine and a promising target for combination therapy for cancer.
Li L; Zhao Y; Cao R; Li L; Cai G; Li J; Qi X; Chen S; Zhang Z
Chem Commun (Camb); 2019 Apr; 55(30):4407-4410. PubMed ID: 30916079
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors.
Jian L; Zscherp R; Beutling U; Shen X; Xu S; Zhang X; Brönstrup M; Klahn P; Sun Q
J Med Chem; 2023 Sep; 66(17):11940-11950. PubMed ID: 37595020
[TBL] [Abstract][Full Text] [Related]
28. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents.
Wang Y; Chang J; Liu X; Zhang X; Zhang S; Zhang X; Zhou D; Zheng G
Aging (Albany NY); 2016 Nov; 8(11):2915-2926. PubMed ID: 27913811
[TBL] [Abstract][Full Text] [Related]
29. Keto-enol-based modification on piperlongumine to generate a potent Cu(II) ionophore that triggers redox imbalance and death of HepG2 cells.
Dai F; Yuan CH; Ji Y; Du YT; Bao XZ; Wu LX; Jin XL; Zhou B
Free Radic Biol Med; 2018 May; 120():124-132. PubMed ID: 29555591
[TBL] [Abstract][Full Text] [Related]
30. [Research progress in anti-tumor activity and nano-drug delivery system of piperlongumine].
Zhang HX; Lin LF; Liu YL; Li H
Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(8):2117-2127. PubMed ID: 38812227
[TBL] [Abstract][Full Text] [Related]
31. Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.
Liu X; Wang Y; Zhang X; Gao Z; Zhang S; Shi P; Zhang X; Song L; Hendrickson H; Zhou D; Zheng G
Bioorg Med Chem; 2018 Aug; 26(14):3925-3938. PubMed ID: 29925484
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibitors of nuclear export (SINE) in hematological malignancies.
Das A; Wei G; Parikh K; Liu D
Exp Hematol Oncol; 2015; 4():7. PubMed ID: 25745591
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting cancer cell hallmark features through nuclear export inhibition.
Sun Q; Chen X; Zhou Q; Burstein E; Yang S; Jia D
Signal Transduct Target Ther; 2016; 1():16010. PubMed ID: 29263896
[TBL] [Abstract][Full Text] [Related]
34. Piperlongumine is a ligand for the orphan nuclear receptor 4A1 (NR4A1).
Zhang L; Martin G; Mohankumar K; Wright GA; Mariyam F; Safe S
Front Pharmacol; 2023; 14():1223153. PubMed ID: 37808182
[TBL] [Abstract][Full Text] [Related]
35. Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine.
Prasad S; Tyagi AK
Curr Pharm Des; 2016; 22(27):4151-9. PubMed ID: 27262330
[TBL] [Abstract][Full Text] [Related]
36. Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance.
Machado S; Silva A; De Sousa-Coelho AL; Duarte I; Grenho I; Santos B; Mayoral-Varo V; Megias D; Sánchez-Cabo F; Dopazo A; Ferreira BI; Link W
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33316942
[TBL] [Abstract][Full Text] [Related]
37. The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates.
Klahn P; Fetz V; Ritter A; Collisi W; Hinkelmann B; Arnold T; Tegge W; Rox K; Hüttel S; Mohr KI; Wink J; Stadler M; Wissing J; Jänsch L; Brönstrup M
Chem Sci; 2019 May; 10(20):5197-5210. PubMed ID: 31191875
[TBL] [Abstract][Full Text] [Related]
38. Metabolic profile and safety of piperlongumine.
de Lima Moreira F; Habenschus MD; Barth T; Marques LM; Pilon AC; da Silva Bolzani V; Vessecchi R; Lopes NP; de Oliveira AR
Sci Rep; 2016 Sep; 6():33646. PubMed ID: 27681015
[TBL] [Abstract][Full Text] [Related]
39. Correction to Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
Zou Y; Zhao D; Yan C; Ji Y; Liu J; Xu J; Lai Y; Tian J; Zhang Y; Huang Z
J Med Chem; 2020 Jan; 63(2):880-881. PubMed ID: 31898900
[No Abstract] [Full Text] [Related]
40. Kidney cancer: CRM1-a novel drug target for renal cell carcinoma?
Payton S
Nat Rev Urol; 2012 Dec; 9(12):672. PubMed ID: 23147926
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
